Singapore wealthtech Endowus secures investment from UBS, Samsung and Singtel finextra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finextra.com Daily Mail and Mail on Sunday newspapers.
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Quantum Dot Sensors Market– Global.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Feb 12 2021 Read 707 Times
AffyXell Therapeutics, a joint venture between Avacta Group and Daewoong Pharmaceutical (Seoul) has closed a Series A venture capital investment of $7.3 million to develop genetically modified stem cells that will produce and secrete therapeutic proteins in situ in the patient.
Established in January 2020, AffyXell has combined Avacta’s Affimer platform with Daewoong’s mesenchymal stem cell (lMSC) platform to produce Affimer molecules generated to suppress immune response and restore immune balance.
While initially focusing on inflammatory and autoimmune diseases and prevention of organ transplant rejection, longer term goals could also include applications in regenerative medicine, infectious diseases and oncology.